Diane Gosselin appointed President and Chief Executive Officer of CQDM

MONTREAL, Nov. 23, 2012 /CNW Telbec/ - Mr. Léon Gosselin, Chairman of the Board of the Québec Consortium for Drug Discovery (CQDM), is pleased to announce the appointment of Mrs. Diane Gosselin (no family relationship) as President and Chief Executive Officer. Ms. Gosselin will be replacing Mr. Max Fehlmann who announced today his resignation from CQDM in order to take on the position of Chief Executive Officer of NEOMED. However, the CQDM will continue to benefit from Mr. Fehlmann's input as Strategic Advisor and member of the Board of Directors.

"CQDM is a proud contributor to the creation of NEOMED whose mission complements our own," declared Diane Gosselin. While NEOMED will focus on developing new drugs, CQDM remains dedicated to the development of tools that enable drug development. "We will pursue our development based on our unique business model where partners share the results of their research projects. The results obtained to date clearly demonstrate that our business model offers tangible results that strongly impact the biopharmaceutical research sector," she added.

Mrs. Gosselin joined CQDM in September 2008 as Vice President, Research and Business Development and was responsible for establishing all funding programs and managing the Company's corporate development activities. She boasts some twenty years of experience in research and corporate financing, namely at Fonds de solidarité FTQ where she helped several companies implement their drug development strategy. At PROCREA BioSciences, she supervised the research team that created and developed the first non-invasive diagnostic test for endometriosis. Mrs. Gosselin holds a Ph.D. in microbiology and immunology from Université de Montréal, as well as an Executive MBA from the Université du Québec à Montréal and Université Paris-Dauphine.

About CQDM

The Québec Consortium for Drug Discovery (CQDM) is a hub for all stakeholders in biopharmaceutical research. Its principal mission is to fund joint research projects between the academic and private sectors. An innovative Canadian initiative, the CQDM has a twofold goal: to accelerate the drug discovery process and to develop safer and more effective drugs. Project funding is made possible through contributions from Pfizer Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd.,  GlaxoSmithKline Inc., Eli Lilly Canada Inc., the Business-Led Networks of Centres of Excellence (BL-NCE), the Ministère de l'Enseignement Supérieur et de la Science of Quebec and the Fonds de recherche Québec - Santé (FRQS). For more information, visit www.cqdm.org.

SOURCE: CQDM

For further information:

Suzanne Gagnon
Phone: 514-985-8211
Cell.: 514 386-8211
suzanne.gagnon@citoyenoptimum.com